Search Results | Cancer Research | American Association for Cancer Research

1-20 of 44

2 3

Sort by

Sort Order Select

Journal Articles

Abstract 5740: Identification of genetic signatures in bone metastasis of breast and prostate cancer

Tiina E. Kähkönen, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2022) 82 (12_Supplement): 5740.

DOI: https://doi.org/10.1158/1538-7445.AM2022-5740

Published: 15 June 2022

View article

Journal Articles

Abstract 2870: Limited data from clinical trials assessing immunotherapy effects on bone metastases

Tiina E. Kähkönen, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2021) 81 (13_Supplement): 2870.

DOI: https://doi.org/10.1158/1538-7445.AM2021-2870

Published: 01 July 2021

View article

Journal Articles

Abstract 1634: Orthotopic and bone metastasis prostate cancer models using the 22Rv1 cell line

Justyna Zdrojewska, Tiina E. Kähkönen, Jenni H. Mäki-Jouppila, Masi Valkonen, Pekka Ruusuvuori, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2020) 80 (16_Supplement): 1634.

DOI: https://doi.org/10.1158/1538-7445.AM2020-1634

Published: 15 August 2020

View article

Journal Articles

Abstract 2759: Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro

Jenni H. Mäki-Jouppila, Jussi M. Halleen, Katja M. Fagerlund

Cancer Res (2020) 80 (16_Supplement): 2759.

DOI: https://doi.org/10.1158/1538-7445.AM2020-2759

Published: 15 August 2020

View article

Journal Articles

Abstract 6286: The effects of prednisone, abiraterone acetate and radium-223 dichloride on bone in the intratibial LNCaP prostate cancer model

Mari I. Suominen, Matias Knuuttila, Birgitta Sjöholm, Esa Alhoniemi, Dominik Mumberg, Jussi M. Halleen, Sanna-Maria Käkönen, Arne Scholz

Cancer Res (2020) 80 (16_Supplement): 6286.

DOI: https://doi.org/10.1158/1538-7445.AM2020-6286

Published: 15 August 2020

View article

Journal Articles

Abstract 5026: Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer

Tiina Emilia Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2020) 80 (16_Supplement): 5026.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5026

Published: 15 August 2020

View article

Journal Articles

Abstract 4588: Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model

Jenni H. Mäki-Jouppila, Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2019) 79 (13_Supplement): 4588.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4588

Published: 01 July 2019

View article

Journal Articles

Abstract 2814: Systemic and local bone metastasis models for immuno-oncology drug development

Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jussi M. Halleen, Arne Scholz, Jenni Bernoulli

Cancer Res (2019) 79 (13_Supplement): 2814.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2814

Published: 01 July 2019

View article

Journal Articles

Abstract 4616: Establishment of a metastatic orthotopic model of pancreatic ductal adenocarcinoma (PDAC) for drug development

Justyna Zdrojewska, Jenni H.E. Mäki-Jouppila, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2019) 79 (13_Supplement): 4616.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4616

Published: 01 July 2019

View article

Journal Articles

Abstract 4614: Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies

Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jussi M. Halleen, Jenni Bernoulli, Derek Grant

Cancer Res (2019) 79 (13_Supplement): 4614.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4614

Published: 01 July 2019

View article

Journal Articles

Abstract 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice

Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Birgitta Sjöholm, Ilmari Ahonen, Dominik Mumberg, Karl Ziegelbauer, Jussi M. Halleen, Sanna-Maria Käkönen, Arne Scholz

Cancer Res (2019) 79 (13_Supplement): 3936.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3936

Published: 01 July 2019

View article

Journal Articles

Abstract 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer

Justyna Zdrojewska, Mari I. Suominen, Katja M. Fagerlund, Jussi M. Halleen, Jenni Bernoulli, Johann Zimmermann

Cancer Res (2019) 79 (13_Supplement): 2007.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2007

Published: 01 July 2019

View article

Journal Articles

Abstract 2161: In vitro osteoblast assays for studying the effects of cancer therapeutics on bone biology

Jenni H. Mäki-Jouppila, Jussi M. Halleen, Katja Fagerlund

Cancer Res (2019) 79 (13_Supplement): 2161.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2161

Published: 01 July 2019

View article

Journal Articles

Abstract 4850: The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer

Tiina E. Kähkönen, Jenni H.E. Mäki-Jouppila, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2019) 79 (13_Supplement): 4850.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4850

Published: 01 July 2019

View article

Journal Articles

Abstract 1738: PD-1/PD-L1 expression and tumor-infiltrating immune cells in triple-negative breast cancer: Characterization of preclinical primary tumor and bone metastasis models in humanized mice

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Azusa Tanaka, Michael Seiler, Teppo Haapaniemi, Jenni Bernoulli

Cancer Res (2018) 78 (13_Supplement): 1738.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1738

Published: 01 July 2018

View article

Journal Articles

Abstract 1677: Differential efficacy of PD-1 targeted immunomodulation in preclinical models of primary and bone metastatic triple-negative breast cancer

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Teppo Haapaniemi, Azusa Tanaka, Michael Seiler, Jenni Bernoulli

Cancer Res (2018) 78 (13_Supplement): 1677.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1677

Published: 01 July 2018

View article

Journal Articles

Abstract 1158: Phenotypic screening using AMIDA identifies different drug responses in breast and prostate cancer cell lines in an organotypic cell culture model

Mervi Toriseva, Katja Fagerlund, Jesse Mattsson, Tiina E. Kähkönen, Ilmari Ahonen, Malin Åkerfelt, Jenni Bernoulli, Jussi M. Halleen, Matthias Nees, Jenni H. Mäki-Jouppila

Cancer Res (2018) 78 (13_Supplement): 1158.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1158

Published: 01 July 2018

View article

Journal Articles

Abstract 1162: Castration-resistant prostate cancer bone metastasis model to assess new therapeutics

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli, Pascale Lejeune

Cancer Res (2018) 78 (13_Supplement): 1162.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1162

Published: 01 July 2018

View article

Journal Articles

Abstract 2684: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies targeting HER2-positive breast cancer

Jenni H. Mäki-Jouppila, Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli, Jani Saarela, Katja Fagerlund

Cancer Res (2018) 78 (13_Supplement): 2684.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2684

Published: 01 July 2018

View article

Journal Articles

Abstract 3859: Hormone receptor and HER2/HER3 expression in preclinical breast cancer models of primary tumor and bone metastasis

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni H. Mäki-Jouppila, Azusa Tanaka, Michael Seiler, Teppo Haapaniemi, Jenni Bernoulli

Cancer Res (2018) 78 (13_Supplement): 3859.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3859

Published: 01 July 2018

View article

2 3

NARROW

Abstract 5740: Identification of genetic signatures in bone metastasis of breast and prostate cancer

Abstract 2870: Limited data from clinical trials assessing immunotherapy effects on bone metastases

Abstract 1634: Orthotopic and bone metastasis prostate cancer models using the 22Rv1 cell line

Abstract 2759: Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro

Abstract 6286: The effects of prednisone, abiraterone acetate and radium-223 dichloride on bone in the intratibial LNCaP prostate cancer model

Abstract 5026: Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer

Abstract 4588: Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model

Abstract 2814: Systemic and local bone metastasis models for immuno-oncology drug development

Abstract 4616: Establishment of a metastatic orthotopic model of pancreatic ductal adenocarcinoma (PDAC) for drug development

Abstract 4614: Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies

Abstract 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice

Abstract 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer

Abstract 2161: In vitro osteoblast assays for studying the effects of cancer therapeutics on bone biology

Abstract 4850: The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer

Abstract 1738: PD-1/PD-L1 expression and tumor-infiltrating immune cells in triple-negative breast cancer: Characterization of preclinical primary tumor and bone metastasis models in humanized mice

Abstract 1677: Differential efficacy of PD-1 targeted immunomodulation in preclinical models of primary and bone metastatic triple-negative breast cancer

Abstract 1158: Phenotypic screening using AMIDA identifies different drug responses in breast and prostate cancer cell lines in an organotypic cell culture model

Abstract 1162: Castration-resistant prostate cancer bone metastasis model to assess new therapeutics

Abstract 2684: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies targeting HER2-positive breast cancer

Abstract 3859: Hormone receptor and HER2/HER3 expression in preclinical breast cancer models of primary tumor and bone metastasis

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only